PharmaDeals Review Business Commentaries
Dr Fintan Walton, PharmaVentures’ CEO, provides monthly comment on topical biotechnology and pharmaceutical industry issues. Includes access to Fintan’s commentaries broadcast on PharmaTelevision.
Available as PDF
(Subscribers only)
GSK Keeps an Eye on Vaccines Business with Potential ID Biomedical Acquisition
From issue 64 of the PharmaDeals Review (2005-10-01)
Despite being the biggest vaccines deal in history, the announcement of this alliance was met with a largely negative response from ID Biomedical shareholders. In this feature, we examine the reasons for the downbeat reaction to yet another potential biotech acquisition by a big pharma.
Available as PDF
(Subscribers only)
EpiCept Merges with Maxim to Go Public
From issue 64 of the PharmaDeals Review (2005-10-01)
Following two failed attempts at an IPO, EpiCept has now gone down the M&A route to gain a public listing by agreeing to merge with the now struggling Maxim Pharmaceuticals. This feature considers the recent activities and issues surrounding the two companies that have driven them to enter into such a transaction.
Available as PDF
(Subscribers only)
When and How to Find the Right Partner
From issue 64 of the PharmaDeals Review (2005-10-01)
This article, which is adapted from the 2005 PharmaVentures report Strategies and Tactics for Successful Partnering, presents guidelines for choosing the right partner. Aspects discussed include when to partner, the criteria for partner selection and the means by which a partner may be identified.
Available as PDF
(Subscribers only)
Therapy Focus: Schizophrenia
From issue 64 of the PharmaDeals Review (2005-10-01)
Schizophrenia is the most common severe mental disorder. This psychotic illness can be characterised by either positive symptoms (such as delusions) and negative symptoms (such as tiredness and loss of concentration). The article discusses current treatments for the disease (typical/conventional antipsychotics and atypical antipsychotics), deal making trends, the future of atypical antipsychotics, and the discovery and development of novel antipsychotics.
Available as PDF
(Subscribers only)
AstraZeneca and Early-Stage Deal Making
From issue 63 of the PharmaDeals Review (2005-09-01)
After having been relatively quiet on the deal making front for some time, AstraZeneca recently established three noteworthy research partnerships with AVANIR Pharmaceuticals, Astex Therapeutics and Schering. This feature considers AstraZeneca's rationale for entering into such agreements and why its early-stage partnering strategy is eminently sensible.
Last Issue PDF
RSS